Figure 6.

Proportion of subjects in weight management trial NCT02453711 with metabolic syndrome at baseline, week 28 and week 52 of treatment with once‐daily semaglutide or placebo (observed data). ALT, alanine aminotransferase. Metabolic syndrome was defined as three or more of: waist circumference ≥89 cm (women) or ≥102 cm (men); triglycerides ≥1.7 mmol/L; high‐density lipoprotein‐cholesterol <1.3 mmol/L (women) or <1.04 mmol/L (men); systolic blood pressure ≥130 mmHg and diastolic blood pressure ≥85 mmHg; fasting plasma glucose ≥5.6 mm/L